JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

Search

Omnicell Inc

Abierto

SectorSanidad

33.4 -0.48

Resumen

Variación precio

24h

Actual

Mínimo

32.8

Máximo

33.81

Métricas clave

By Trading Economics

Ingresos

13M

5.6M

Ventas

21M

291M

P/B

Media del Sector

61.08

37.003

Margen de beneficios

1.941

Empleados

3,650

EBITDA

42M

30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+31.81% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

44M

1.4B

Apertura anterior

33.88

Cierre anterior

33.4

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

67 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Omnicell Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 nov 2025, 22:13 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov 2025, 21:23 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov 2025, 23:34 UTC

Charlas de Mercado

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov 2025, 20:45 UTC

Ganancias

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov 2025, 20:44 UTC

Ganancias

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov 2025, 20:43 UTC

Ganancias

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov 2025, 20:42 UTC

Ganancias

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov 2025, 20:41 UTC

Ganancias

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov 2025, 20:40 UTC

Ganancias

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov 2025, 20:39 UTC

Ganancias

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov 2025, 20:36 UTC

Ganancias

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov 2025, 20:34 UTC

Ganancias

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov 2025, 20:33 UTC

Ganancias

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov 2025, 14:27 UTC

Ganancias

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov 2025, 14:25 UTC

Ganancias

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparación entre iguales

Cambio de precio

Omnicell Inc previsión

Precio Objetivo

By TipRanks

31.81% repunte

Estimación a 12 Meses

Media 44.25 USD  31.81%

Máximo 55 USD

Mínimo 34 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omnicell Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

24.23 / 30.44Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

67 / 373 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat